[Sulindac in the treatment of soft tissue rheumatism (periarthropathy of the hip and shoulder (author's transl)].
Sulindac (Clinoril) was tested in an open clinical-therapeutical study with regard to its analgesic effect and the improvement of function in 20 patients of both sexes suffering from periarthropathy of the hip or shoulder. The treatment lasted 4 weeks. The therapeutic effect was judged on the basis of the influence on the spontaneous pain and on the pain by pressure, on the functional improvement and on the daily habits of the patients. It was noted, that there was a lasting improvement due to the analgesic effect already in the first week of therapy and an improvement of function in the second week of therapy in the majority of the cases. Sulindac was well tolerated. Laboratory findings in the beginning and at the end of the four weeks treatment period revealed no toxic effects on organs, particularly on hematopoietic system.
D000328:Adult; D000368:Aged; D004361:Drug Tolerance; D005260:Female; D006207:Half-Life; D006801:Humans; D007192:Indenes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010489:Periarthritis / Q000188:drug therapy*; D013467:Sulindac / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D007192:Indenes; D013467:Sulindac
Sulindac in der Behandlung des Weichteilrheumatismus (Periarthropathia humeri et coxae).